Skip to main content
Erschienen in: Diabetologia 7/2017

22.03.2017 | Article

Decreased basal hepatic glucose uptake in impaired fasting glucose

verfasst von: Mariam Alatrach, Christina Agyin, John Adams, Ralph A. DeFronzo, Muhammad A. Abdul-Ghani

Erschienen in: Diabetologia | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

This research aimed to define the pathophysiological defects responsible for the elevated fasting plasma glucose (FPG) concentration and excessive rise in post-load plasma glucose observed in individuals with impaired fasting glucose (IFG).

Methods

We used tracer techniques to quantify basal splanchnic (primarily hepatic) glucose uptake and glucose fluxes following glucose ingestion in individuals with normal glucose tolerance (NGT; n = 10) and IFG (n = 10).

Results

Individuals with IFG had a comparable basal rate of hepatic glucose production to those with NGT (15.2 ± 0.2 vs 18.0 ± 0.8 μmol min−1 [kg lean body mass (LBM)]−1; p = 0.09). However, they had a significantly reduced glucose clearance rate during the fasting state compared with NGT (2.64 ± 0.11 vs 3.62 ± 0.20 ml min−1 [kg LBM]−1; p < 0.01). The difference between the basal rate of glucose appearance measured with [3-3H]glucose and [1-14C]glucose, which represent basal splanchnic glucose uptake, was significantly reduced in IFG compared with NGT (1.39 ± 0.28 vs 3.16 ± 0.44 μmol min−1 [kg LBM]−1; p = 0.02). Following glucose ingestion, the total amount of exogenous glucose that appeared in the systemic circulation was not significantly different between groups. However, suppression of endogenous glucose production (EGP) was markedly impaired in individuals with IFG.

Conclusions/interpretation

These results demonstrate that decreased tissue (liver) glucose uptake, not enhanced EGP, is the cause for elevated FPG concentration in individuals with IFG, while the excessive rise in plasma glucose concentration following a glucose load in these individuals is the result of impaired suppression of hepatic glucose production.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197CrossRef The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197CrossRef
2.
Zurück zum Zitat Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:708–723CrossRefPubMed Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:708–723CrossRefPubMed
3.
Zurück zum Zitat Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006a) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130–1139CrossRefPubMed Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006a) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130–1139CrossRefPubMed
4.
Zurück zum Zitat Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA (2006b) Insulin secretion and action in subjectswith impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55:1430–1435CrossRefPubMed Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA (2006b) Insulin secretion and action in subjectswith impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55:1430–1435CrossRefPubMed
5.
Zurück zum Zitat Weyer C, Bogardus C, Pratley RE (1999) Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197–2203CrossRefPubMed Weyer C, Bogardus C, Pratley RE (1999) Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197–2203CrossRefPubMed
6.
Zurück zum Zitat Bock G, Chittilapilly E, Basu R et al (2007) Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes 56:1703–1711CrossRefPubMed Bock G, Chittilapilly E, Basu R et al (2007) Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes 56:1703–1711CrossRefPubMed
7.
Zurück zum Zitat Cali’ AM, Bonadonna RC, Trombetta M, Weiss R, Caprio S (2008) Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab 93:1767–1773CrossRefPubMedPubMedCentral Cali’ AM, Bonadonna RC, Trombetta M, Weiss R, Caprio S (2008) Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab 93:1767–1773CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Bacha F, Lee S, Gungor N, Arslanian SA (2010) From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care 33:2225–2231CrossRefPubMedPubMedCentral Bacha F, Lee S, Gungor N, Arslanian SA (2010) From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care 33:2225–2231CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Bock G, Dalla Man C, Campioni M et al (2006) Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 55:3536–3549CrossRefPubMed Bock G, Dalla Man C, Campioni M et al (2006) Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 55:3536–3549CrossRefPubMed
10.
Zurück zum Zitat Abdul-Ghani MA, Abdul-Ghani TA, Ali N, DeFronzo RA (2008) One hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31:1650–1655CrossRefPubMedPubMedCentral Abdul-Ghani MA, Abdul-Ghani TA, Ali N, DeFronzo RA (2008) One hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31:1650–1655CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Abdul-Ghani MA, Williams K, DeFronzo RA, Stern MP (2007) What is the best predictor for future type 2 diabetes? Diabetes Care 30:1544–1548CrossRefPubMed Abdul-Ghani MA, Williams K, DeFronzo RA, Stern MP (2007) What is the best predictor for future type 2 diabetes? Diabetes Care 30:1544–1548CrossRefPubMed
12.
Zurück zum Zitat Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L (2009) Fasting versus post load plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia study. Diabetes Care 32:281–286CrossRefPubMedPubMedCentral Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L (2009) Fasting versus post load plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia study. Diabetes Care 32:281–286CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Cervera A, Wajcberg E, Sriwijitkamol A et al (2008) Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 294:E846–E852CrossRefPubMed Cervera A, Wajcberg E, Sriwijitkamol A et al (2008) Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 294:E846–E852CrossRefPubMed
14.
Zurück zum Zitat Polidori D, Sha S, Mudaliar S et al (2013) Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36:2154–2161CrossRefPubMedPubMedCentral Polidori D, Sha S, Mudaliar S et al (2013) Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36:2154–2161CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Camastra S, Muscelli E, Gastaldelli A et al (2013) Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients. Diabetes 62:3709–3717CrossRefPubMedPubMedCentral Camastra S, Muscelli E, Gastaldelli A et al (2013) Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients. Diabetes 62:3709–3717CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Rizza RA, Toffolo G, Cobelli C (2016) Accurate measurement of postprandial glucose turnover: why is it difficult and how can it be done (relatively) simply? Diabetes 65:1133–1145CrossRefPubMedPubMedCentral Rizza RA, Toffolo G, Cobelli C (2016) Accurate measurement of postprandial glucose turnover: why is it difficult and how can it be done (relatively) simply? Diabetes 65:1133–1145CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Ter Horst KW, Gilijamse PW, Ackermans MT et al (2016) Impaired insulin action in the liver, but not in adipose tissue or muscle, is a distinct metabolic feature of impaired fasting glucose in obese humans. Metabolism 65:757–763CrossRefPubMed Ter Horst KW, Gilijamse PW, Ackermans MT et al (2016) Impaired insulin action in the liver, but not in adipose tissue or muscle, is a distinct metabolic feature of impaired fasting glucose in obese humans. Metabolism 65:757–763CrossRefPubMed
18.
Zurück zum Zitat Perreault L, Man CD, Hunerdosse DM, Cobelli C, Bergman BC (2010) Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose. Diabetes Res Clin Pract 90:87–94CrossRefPubMed Perreault L, Man CD, Hunerdosse DM, Cobelli C, Bergman BC (2010) Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose. Diabetes Res Clin Pract 90:87–94CrossRefPubMed
19.
Zurück zum Zitat Perreault L, Bergman BC, Playdon MC, Dalla Man C, Cobelli C, Eckel RH (2008) Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes? Am J Physiol Endocrinol Metab 295:E428–E435CrossRefPubMedPubMedCentral Perreault L, Bergman BC, Playdon MC, Dalla Man C, Cobelli C, Eckel RH (2008) Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes? Am J Physiol Endocrinol Metab 295:E428–E435CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Tripathy D, Carlsson M, Almgren P et al (2000) Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 49:975–980CrossRefPubMed Tripathy D, Carlsson M, Almgren P et al (2000) Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 49:975–980CrossRefPubMed
21.
Zurück zum Zitat Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T (2003) Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose. Diabetes Care 26:868–874CrossRefPubMed Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T (2003) Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose. Diabetes Care 26:868–874CrossRefPubMed
22.
Zurück zum Zitat Basu R, Barosa C, Jones J et al (2013) Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia. J Clin Endocrinol Metab 98:E409–E417CrossRefPubMedPubMedCentral Basu R, Barosa C, Jones J et al (2013) Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia. J Clin Endocrinol Metab 98:E409–E417CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat DeFronzo RA, Ferrannini E, Simonson DC (1989) Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387–395CrossRefPubMed DeFronzo RA, Ferrannini E, Simonson DC (1989) Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387–395CrossRefPubMed
24.
Zurück zum Zitat Jeng CY, Sheu WH, Fuh MM, Chen YD, Reaven GM (1994) Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 43:1440–1444CrossRefPubMed Jeng CY, Sheu WH, Fuh MM, Chen YD, Reaven GM (1994) Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 43:1440–1444CrossRefPubMed
25.
Zurück zum Zitat Jani R, Molina M, Matsuda M et al (2008) Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. Diabetes Care 31:311–315CrossRefPubMed Jani R, Molina M, Matsuda M et al (2008) Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. Diabetes Care 31:311–315CrossRefPubMed
26.
Zurück zum Zitat RA DF Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37(667–687):1988 RA DF Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37(667–687):1988
27.
Zurück zum Zitat DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J (1983) Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes 32:35–45CrossRefPubMed DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J (1983) Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes 32:35–45CrossRefPubMed
28.
Zurück zum Zitat Perreault L, Færch K, Kerege AA, Bacon SD, Bergman BC (2014) Hepatic glucose sensing is impaired, but can be normalized, in people with impaired fasting glucose. J Clin Endocrinol Metab 99:E1154–E1162CrossRefPubMedPubMedCentral Perreault L, Færch K, Kerege AA, Bacon SD, Bergman BC (2014) Hepatic glucose sensing is impaired, but can be normalized, in people with impaired fasting glucose. J Clin Endocrinol Metab 99:E1154–E1162CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E (2000) Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). Diabetologia 43:1266–1272CrossRefPubMed Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E (2000) Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). Diabetologia 43:1266–1272CrossRefPubMed
Metadaten
Titel
Decreased basal hepatic glucose uptake in impaired fasting glucose
verfasst von
Mariam Alatrach
Christina Agyin
John Adams
Ralph A. DeFronzo
Muhammad A. Abdul-Ghani
Publikationsdatum
22.03.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 7/2017
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4252-0

Weitere Artikel der Ausgabe 7/2017

Diabetologia 7/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.